The terms of this agreement are subject to certain provisions and performance targets as outlined in Lev’s filing on Form 8-K with the Securities and Exchange Commission.
Judson Cooper, chairman of Lev, said: “This agreement is aimed at providing Lev with an ancillary source of US plasma supply in anticipation of launch of our lead product candidate, Cinryze, for the treatment of hereditary angioedema, upon FDA approval.”